jnj-26489112 jnj-26489112 jnj-26489112 is an anticonvulsant drug being developed by johnson & johnson for the treatment of epilepsy. jnj-26489112 was designed as a successor to topiramate. it is expected to have fewer side effects than topiramate because it lacks activity against carbonic anhydrase. jnj-26489112identifiers iupac name (s)-n-dioxin-2-yl)methyl]sulfamide cas number871824-55-4 ypubchem cid11616111chemspider9790860uniig1ti012dltchemical and physical dataformulac9h11cln2o4smolar mass278.71 g·mol−13d model (jsmol)interactive image smiles ns(=o)(=o)nc1coc2=c(o1)c=cc(cl)=c2 inchi inchi=1s/c9h11cln2o4s/c10-6-1-2-8-9(3-6)15-5-7(16-8)4-12-17(11,13)14/h1-3,7,12h,4-5h2,(h2,11,13,14)/t7-/m0/s1key:kxsaiqppgssnkx-zetcqymhsa-n jnj-26489112 was studied as a treatment for major depressive disorder. this clinical trial was terminated in 2013 due to a "sponsor portfolio decision", and no new development of jnj-26489112 has been reported. its mechanism of action is unknown.